Description

Ipamorelin is a penta-peptide hormone (Aib-His-D-2-Nal-D-Phe-Lys-NH2), a growth hormone secretagogue and a small molecule ghrelin mimetic developed by Novo Nordisk. Ipamorelin belongs to the most recent generation of GHRPs and causes significant release of growth hormone.

Similar to GHRP-6 and GHRP-2, it suppresses somatostatin and increases the stimulation and release of Growth Hormone (GH) from the anterior pituitary. Currently, there are few clinical trials involving Ipamorelin, which were first being studied in the 90s. Ipamorelin significantly increases plasma growth hormone (GH) levels in both animals and humans. In addition, ipamorelin stimulates body weight gain in animals. Like GHRP-6, ipamorelin does not affect prolactin, follicle-stimulating hormone (FSH), luteinizing hormone (LH), or thyroid-stimulating hormone (TSH) levels.

CJC-1295 is a tetrasubstituted 30-amino acid peptide hormone, primarily functioning as a growth hormone releasing hormone (GHRH) analog. It has D-Ala, Gln, Ala, and Leu substitutions at positions 2, 8, 15, and 27 respectively.

Ipamorelin & CJC-1295 Combo are sterile, non-pyrogenic, white lyophilized powder intended for subcutaneous or intramuscular injection, after reconstitution with sterile Water for Injection (0,3% m-Cresol).

Adverse reaction

Both Ipamorelin and CJC-1295 are generally very well tolerated by most individuals when used at the recommended dosages of about 100mcg per injection.

- Water Retention

- Tiredness

- Increased Hunger

- Head immediately after the injection

- Increased hunger

Dosage

Recommended dosage for mixture of Ipamorelin & CJC-1295: 200mcg (0.10mg) once per day for anti-aging. Between 800-1200 mcgs, divided in two or three doses per day for muscle gain and fat loss, directed via subcutaneous injections.